|
Cyberonics makes the first medical device to be cleared by the FDA for treating epilepsy. The company's VNS Therapy System is a pacemaker-like device implanted under the collarbone with a lead attached to the vagus nerve in the neck. The device delivers intermittent signals to the brain, dubbed vagus nerve stimulation (VNS), to control epileptic seizures. The signals can be programmed by a physician using a computer, and patients can stop or start signals with a hand-held magnet. The system is also approved for use in Australia, Canada, the EU, and some Asian and Latin American countries. The VNS system is being studied as a potential treatment for conditions such as bulimia and Alzheimer's disease.
|
| | | Contact Information | |
Address: |
Cyberonics Bldg., 100 Cyberonics Blvd.
Houston, TX 77058-2072
| | Phone: | 281-228-7200 | | Fax: | 281-218-9332 |
|
| Financial
Highlights | | Fiscal Year End: | April | | Revenue (2009): | 143.60 M | | Revenue Growth (1 yr): | 18.50% | | Employees (2009): | 440 | | Employee Growth (1 yr): | 0.50% |
|
|
Key People
| | • |
Chairman:
Hugh M. Morrison
| | • |
President, CEO, and Director:
Daniel J. (Dan) Moore
| | • |
VP Operations:
Randal L. Simpson
|
|
|
